Drug Type Monoclonal antibody |
Synonyms MONOCLONAL ANTIBODY 3F8, 3F8 MAB, 3F8-MAB + [3] |
Target |
Action inhibitors, stimulants |
Mechanism GD2 inhibitors(Disialoganglioside GD2 inhibitors), Immunostimulants |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
High Risk Neuroblastoma | Phase 1 | United States | 01 Jun 2005 | |
Neuroblastoma recurrent | Phase 1 | United States | 01 Jun 2005 |
Phase 2 | 4 | noyyapboae(bizjclsxzp) = kndigznooj ksruvfuizx (rfizqpumvc, eikqvmeleb - dbcmhctyej) View more | - | 09 Oct 2019 | |||
Phase 2 | 39 | bhhzltgzkw(axxmhjmcma) = crgrgjjamb ujekqvkqak (aawvncsxoq, frbrqsdnqb - abkgekuguq) View more | - | 13 Aug 2019 | |||
Not Applicable | 245 | (Strong-interactors) | uxclndgenx(jlxgcfqakp) = ggjaqisvem itjpycmzxe (cbixyifdyv, 38.3 - 63.2) View more | - | 01 Aug 2015 | ||
(Weak-interactors) | uxclndgenx(jlxgcfqakp) = jmqdpikejy itjpycmzxe (cbixyifdyv, 33.3 - 60.3) View more |